Drug testing revealed that bleomycin and sirolimus effectively inhibited CD31-positive noninvoluting congenital hemangioma endothelial cells proliferation, with combination therapy showing significant tumor regression in vivo. This evidence concerns the gene PECAM1 and neoplasm.